One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …

Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of
genotype 1-infected patients. Antiviral agents specifically targeting either the HCV protease …

Chronic infection with hepatitis C virus is a major cause of liver disease and hepatocellular
carcinoma worldwide. After the discovery of hepatitis C virus 3 decades ago, the …

Introduction: Rapid breakthroughs in the treatment of hepatitis C virus (HCV) infection have
dramatically altered the treatment landscape for this chronic disease. In 2011, the protease …

There has been a revolution in the treatment of chronic hepatitis C. Several oral regimens
combining direct‐acting antivirals (DAA s) from different families [NS 5B nucleotide …

Today, hepatitis C virus infection affects up to 1.5 million people per year and is responsible
for 29 thousand deaths per year. In the 1970s, the clinical observation of unclear, transfusion …

Antiviral therapy for chronic hepatitis C has dramatically advanced since the discovery of the
hepatitis C virus (HCV) in 1989 and the introduction of interferon (IFN) monotherapy in the …

Introduction: The development of direct-acting antiviral (DAA) agents for the treatment of
hepatitis C virus (HCV) infection has completely transformed the management of this …

Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which
is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, or …

Objectives Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical
and social problem. The expanding knowledge of HCV lifecycle has led to the development …